Skip to main content
    P

    Pulse Biosciences Inc (PLSE)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $44.84
    -1.52 (-3.28%)

    Market Cap: $3.71B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Pulse Biosciences Inc (PLSE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Pulse Biosciences (PLSE) has a market cap of $3.71B and an enterprise value of $3.67B. It kept -5603.88% of revenue as net income over the last 12 months. Its share count is up 6.74% from a year earlier.

    Total Valuation

    Enterprise value is 0.99% below the market cap, as cash exceeds debt.

    Market Cap$3.71B
    Enterprise Value$3.67B
    Latest price (Nov 17, 2026)$44.84

    Key Dates

    The next earnings report is expected on Feb 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 17, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 3.94% in the quarter ended Sep 30, 2026 and grew 8.53% a year over 2 years.

    Shares Outstanding71.93M
    Shares Change (YoY)+6.74%
    Shares Change (QoQ)+3.94%
    Share Count Growth (2Y CAGR)+8.53%

    Valuation Ratios

    P/B Ratio17.6x
    P/TBV Ratio17.8x

    Price Statistics

    The stock is up 211.39% over 52 weeks and trades 13.17% below its 50-day average.

    Beta (1Y)2.09
    52-Week Change+211.39%
    1-Month Change-5.70%
    3-Month Change-4.64%
    6-Month Change+79.72%
    5-Year Change+147.70%
    10-Year Change+753.59%
    Total Return (1Y)+211.39%
    Total Return (3Y CAGR)+94.20%
    Total Return (5Y CAGR)+16.98%
    Return vs SPY (1Y)+218.63%
    Max Drawdown (1Y)-29.50%
    Max Drawdown (3Y)-48.45%
    Sharpe Ratio (1Y)1.43
    Correlation with SPY (1Y)0.34
    50-Day Average$51.64
    200-Day Average$33.66
    52-Week Range$12.56 to $58.94
    RSI (14 Days)38.4
    Average Volume (20 Days)422.25K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 14.35x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio14.35x
    Quick Ratio14.33x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -45.61% and return on assets is -41.53% over the last 12 months.

    Return on Equity (ROE)-45.61%
    Return on Assets (ROA)-41.53%
    ROA (5Y Average)-74.31%
    ROIC (5Y Average)-73.72%
    Asset Turnover0.01x
    Inventory Turnover4.68x
    Receivables Turnover7.13x
    Cash Conversion Cycle-847 days

    Scores

    PLSE has an Altman Z-Score of 103.42, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score103.42
    Altman Z ZoneSafe
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $1.49M over the last 12 months is down 14.63% from the 12 months before.

    Revenue$1.49M
    Revenue Growth (YoY)-14.63%
    Gross Profit$400.00K
    Operating Income-$86.97M
    Pretax Income-$83.72M
    Net Income-$83.72M
    Reported EPS (TTM)-$1.10

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 91.07% of the $201.58M in total assets.

    Cash and Equivalents$36.73M
    Total Debt$0
    Net Cash$36.73M
    Net Cash Per Share$0.51
    Working Capital$178.81M
    Shareholder Equity$183.57M
    Book Value Per Share$2.55
    Tangible Book Value$180.73M
    Tangible Book Per Share$2.51
    Total Assets$201.58M
    Total Liabilities$18.01M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $370.00K of capital spending, operating cash flow left -$63.70M of free cash flow.

    Operating Cash Flow-$63.33M
    Capital Expenditures$370.00K
    Free Cash Flow-$63.70M
    FCF Per Share-$0.89
    Depreciation and Amortization$899.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -5821.08%.

    Gross Margin26.77%
    Operating Margin-5821.08%
    Pretax Margin-5603.88%
    Net Margin-5603.88%
    FCF Margin-4263.86%

    Growth

    Revenue fell 20.63% a year over 3 years.

    Revenue Growth (3Y CAGR)-20.63%
    Book Value Per Share Growth (2Y CAGR)+21.88%
    Tangible Book Per Share Growth (2Y CAGR)+26.14%

    Revenue and profit by year

    Dividends and Yields

    PLSE does not pay a dividend. Its free cash flow yield is -1.98%.

    FCF Yield-1.98%
    Buyback Yield-4.45%
    Shareholder Yield-4.45%

    Analyst Forecast

    Consensus estimates put revenue growth at 260.89% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+260.89%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PLSE

    What is PLSE's market cap?

    Pulse Biosciences has a market cap of $3.71B. Its enterprise value, which adds debt and subtracts cash, is $3.67B.

    How many shares of PLSE are outstanding?

    Pulse Biosciences has 71.93M shares outstanding. The count is up 6.74% from a year earlier.

    Does PLSE pay a dividend?

    No. Pulse Biosciences does not pay a dividend.

    How much debt does PLSE have?

    Pulse Biosciences has $0 of total debt and $36.73M of cash and equivalents, a net cash position of $36.73M.